Phase 4 N=25 Geodon in Weight Loss Study for Bipolar Disorders
Bipolar Disorder
Primary: The Primary Outcome Measure Was Weight Change From Baseline to Endpoint. — -9.8 Pounds — p=<0.00001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=42 Efficacy of Amlexanox vs. Placebo in Type 2 Diabetic Patients
Diabetes Mellitus Type 2 · Non-alcoholic Fatty Liver Disease · Obesity
Primary: Difference in Hemoglobin A1c Values — 7.77; 7.68; 7.76; 7.44 percentage of hemoglobin glycated — p=0.05
Phase 2 N=34 Efficacy and Safety of Ryanodex® (EGL-4104) as Adjuvant Treatment in Subjects With Exertional Heat Stroke (EHS)
Heat Stroke
Primary: Number of Subjects Achieving Recovery of Level of Consciousness Defined as a Glasgow Coma Scale (GCS) GCS ≥ 13 — 5; 2 Participants — p=0.396
Phase 3 N=22 Stem Cell Transplant for Hemoglobinopathy
Sickle Cell Disease · Thalassemia · Severe Congenital Neutropenia
Primary: Number of Patients Who Experienced Grade 3-5 Treatment Related Toxicity — 0; 0; 2 Participants
Phase 4 N=88 'Levonorgestrel IUD Insertion After D&E Procedure
Contraceptive Usage
Primary: The Primary Outcome is LNG-IUD Usage Six Months Following Enrollment. — 85.2; 62.9 percentage of participants — p=0.05
Phase 2 N=53 Randomized Controlled Trial of Dexmedetomidine for the Treatment of Intensive Care Unit (ICU) Delirium
Delirium · Agitation
Primary: Resolution of Delirium — 21; 14 Participants
Phase 2 N=140 LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib
Non-Small Cell Lung Cancer
Primary: Overall Response Rate (ORR) to LDK378 Per Investigator Assessment — 40.7 Percentage of participants
N/A N=104 Interbody Fusion Devices in the Treatment of Cervicobrachial Syndrome
Radiating Pain · Myelopathy · Cervicobrachial Syndrome
Primary: Neck Disability Index — 17.9; 16.7 units on a scale from 0 to 100 — p=0.641
Phase 1 N=23 Amendment of rTSST-1 Variant Vaccine Phase 1 Clinical Trial
Toxic-Shock Syndrome · Sepsis
Primary: Number of Participants With Adverse Events as a Measure of Safety — 7; 1; 1; 0 participants
Phase 2 N=8 Donor Peripheral Stem Cell Transplant, Fludarabine, and Busulfan in Treating Patients With Hematologic Cancers
Leukemia · Lymphoma · Multiple Myeloma and Plasma Cell Neoplasm
Primary: Number of Patients With Day 100 Transplant-related Mortality — 1 Participants
Phase 3 N=155 Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy
Head and Neck Cancer · Mucositis · Oral Complications of Radiation Therapy
Primary: Total Pain Reduction (Mouth and Throat) — -9.1; -4.7 units on a scale — p=<0.001
Phase 2 N=119 Gemcitabine and Erlotinib Before and After Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
Pancreatic Cancer
Primary: Overall Survival at 2 Years — 0.54 proportion of patients
Phase 2 N=21 Hydroxychloroquine/Atorvastatin in the Treatment of Osteoarthritis (OA) of the Knee
Osteoarthritis of the Knee
Primary: Change in Synovitis — 9.8 units on a scale
Phase 3 N=283 Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Branch Retinal Vein Occlusion (BRVO)
Macular Edema Secondary to Branch Retinal Vein Occlusion
Primary: Average Change in Best Corrected Visual Acuity (BCVA) From Baseline to Month 1 Through Month 6 — 12.5; 5.0 Letters — p=<0.001
N/A N=67 Automated Folliculometry Using Five-Dimensional Ultrasound
Automated Folliculometry Using Five-Dimensional Ultrasound
Primary: The Mean Follicular Diameter by Two-Dimensional Ultrasound — 8.41 mm